Oncology Product Portfolio
Essential chemotherapy and specialty medicines sourced from EU-GMP and WHO-GMP accredited manufacturers.
MediCore distributes a focused portfolio of oncology and specialty medicines covering the core therapeutic categories used in Nigerian cancer care. Our products are sourced exclusively from manufacturers holding EU-GMP or WHO-GMP accreditation, ensuring pharmaceutical quality standards that meet the expectations of international regulators and Nigerian healthcare providers.
The portfolio is structured around the treatment categories most frequently prescribed in Nigerian oncology practice, from first-line platinum-based regimens to supportive care and oral therapies.
Platinum-Based Chemotherapy
Platinum compounds are among the most widely used chemotherapy agents globally, forming the backbone of first-line treatment protocols for a range of solid tumours including ovarian, lung, colorectal, and head and neck cancers.
Key molecules: Carboplatin, Cisplatin, Oxaliplatin
Taxanes
Taxane-based chemotherapy agents are essential components of treatment regimens for breast cancer, non-small cell lung cancer, ovarian cancer, and other solid tumours. These medicines are used across both curative and palliative treatment settings.
Key molecules: Paclitaxel, Docetaxel
Antimetabolites and Cytotoxic Agents
This category includes core cytotoxic medicines used in standard chemotherapy regimens across multiple cancer types, including colorectal, breast, gastric, and pancreatic cancers. These agents work by disrupting cancer cell replication and are fundamental to combination chemotherapy protocols.
Key molecules: Capecitabine and other standard antimetabolites
Supportive Oncology Medicines
Supportive therapies are administered alongside chemotherapy to manage treatment side effects, reduce complications, and maintain patient quality of life during cancer treatment. This category includes antiemetics, colony-stimulating factors, and other supportive agents essential to safe chemotherapy delivery.
Oral and Endocrine Therapies
Oral anticancer medicines and endocrine therapies are used in the long-term management of hormone-receptor-positive cancers, most commonly breast and prostate cancer. These treatments are often prescribed for extended durations and require reliable, uninterrupted supply.
Key molecules: Tamoxifen, Aromatase inhibitors (anastrozole, letrozole)
Targeted and Specialty Pipeline
MediCore is actively evaluating selected targeted oncology medicines for inclusion in our distribution portfolio. These products represent the next generation of cancer treatment and are under assessment for regulatory pathway feasibility and clinical demand in the Nigerian market.
Sourcing Standards
Every product in the MediCore portfolio is sourced from manufacturers holding current EU-GMP or WHO-GMP accreditation. We conduct documented manufacturer qualification assessments covering regulatory status, manufacturing quality systems, and supply reliability before any product enters our distribution chain.
We do not source from unaccredited manufacturers, and we do not compromise on product quality documentation regardless of commercial pressure or supply urgency.
Product Availability Notice
All products listed are available subject to current NAFDAC registration status and stock levels. Product availability may vary depending on regulatory approvals, manufacturer supply schedules, and import timelines. Contact our team for current availability information.
Professional Audience Disclaimer
The product information on this page is intended for healthcare professionals, hospital procurement teams, and pharmaceutical business partners. It is not intended as medical advice for patients. All prescribing and treatment decisions should be made by qualified healthcare professionals.
Request a Product List
Contact our team to request a detailed product list, discuss specific product availability, or enquire about medicines not currently listed in our portfolio.